| Methods |
Randomized
Multicenter |
| Participants |
Adults (mean ˜ 66)
95% hospitalized
58% CAP (42% bronchitis or COPD exacerbation) |
| Interventions |
Atypical: PO ofloxacin 200 mg X 2/d (several 400 mg X 2/d)
Non‐atypical: PO amoxicillin 750 mg X 3/d (several 375 mg X 4/d) |
| Outcomes |
Clinical |
| Notes |
Another trial reported in same study of non‐randomized CAP suspected of atypical infection; relationship to this trial unclear
Results given are for all patients, including non‐pneumonia
Study in German |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
Mortality |
Low risk |
All patients evaluated |
| Incomplete outcome data (attrition bias)
Failure |
Low risk |
All patients evaluated |
| Selective reporting (reporting bias) |
Low risk |
Not identified |
| Other bias |
Unclear risk |
Sponsored |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
None (open label) |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
None |
